Xiaomei Lu

Xiaomei Lu


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Journal of Cancer
Verified
Journal Article
Open access
QZQiqi Zhang
Qiqi Zhang
QLQing Liu
Qing Liu
SZShutao Zheng
Shutao Zheng
TLTao Liu
Tao Liu
LYLifei Yang
Lifei Yang
XLXiaomei Lu
Xiaomei Lu
Background: Shikonin, a small molecule inhibitor of pyruvate kinase 2 (PKM2), has been demonstrated to play the antitumor effect in various cancers. However, the specific effects and related regulatory mechanism of Shikonin in esophageal squamous cell carcinoma (ESCC) have not been clearly declared.

9 April 2021 in Journal of Physiology and Biochemistry
Verified
Journal Article
Closed access
PDF file
Shutao ZhengShutao Zheng
Shutao Zheng
QLQing Liu
Qing Liu
TLTao Liu
Tao Liu
XLXiaomei Lu
Xiaomei Lu

20 May 2011 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
QLQing Liu
Qing Liu
GLGuo-Dong Lv
Guo-Dong Lv
XQXu Qin
Xu Qin
YGYue-Hua Gen
Yue-Hua Gen
SZShu-Tao Zheng
Shu-Tao Zheng
XLXiaomei Lu
Xiaomei Lu

20 November 2010 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
WMWen-Jing Ma
Wen-Jing Ma
GLGuo-Dong Lv
Guo-Dong Lv
ATAerziguli Tuersun
Aerziguli Tuersun
QLQing Liu
Qing Liu
HLHui Liu
Hui Liu
XLXiaomei Lu
Xiaomei Lu

8 May 2018 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
JZJian Zhou
Jian Zhou
SZShutao Zheng
Shutao Zheng
TLTao Liu
Tao Liu
QLQing Liu
Qing Liu
YCYumei Chen
Yumei Chen
XLXiaomei Lu
Xiaomei Lu

18 February 2021 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
TLTao Liu
Tao Liu
XHXiujuan Han
Xiujuan Han
Shutao ZhengShutao Zheng
Shutao Zheng
QLQing Liu
Qing Liu
ATAerziguli Tuerxun
Aerziguli Tuerxun
XLXiaomei Lu
Xiaomei Lu
Background: Calmodulin1 (CALM1) has been identified as one of the overexpression genes in a variety of cancers and EGFR inhibitor have been widely used in clinical treatment but it is unknown whether CALM1 and epidermal growth factor receptor (EGFR) have a synergistic effect in esophageal squamous cell carcinoma (ESCC). The aim of the present study was to explore the synergistic effects of knock-out CALM1 combined with EGFR inhibitor (Afatinib) and to elucidate the role of CALM1 in sensitizing the resistance to Afatinib in ESCC. Method: Immunohistochemistry (IHC) and qRT-PCR were used to examine the expression of CALM1 and EGFR in ESCC tissues. Kaplan–Meier survival analysis was used to analyze the clinical and prognostic significance of CALM1 and EGFR expression in ESCC. Furthermore, to evaluate the biological function of CALM1 in ESCC, the latest gene editing technique CRISPR/Cas9(Clustered regularly interspaced short palindromic repeats)was applied to knockout CALM1 in ESCC cell lines KYSE150, Eca109 and TE-1. MTT, flow cytometry, Transwell migration, scratch wound-healing and colony formation assays were performed to assay the combined effect of knock-out CALM1 and EGFR inhibitor on ESCC cell proliferation and migration. In addition, nude mice xenograft model was used to observe the synergistic inhibition of knock-out CALM1 and Afatinib. Results: Both CALM1 and EGFR were found to be significantly over-expressed in ESCC compared with paired normal control. Over-expressed CALM1 and EGFR were significantly associated with clinical stage, T classification and poor overall prognosis, respectively. In vitro, the combined effect of knock-out CALM1 mediated by the lentivirus and EGFR inhibitor was shown to be capable of inhibiting the proliferation, inducing cell cycle arrest at G1/S stage and increasing apoptosis of KYSE-150 and Eca109 cells; invasion and migration were also suppressed. In vivo, the results of tumor weight and total fluorescence were markedly reduced compared with the sgCtrl-infected group and sgCAML1 group. Conclusion: Our data demonstrated that knock-out of CALM1 could sensitize ESCC cells to EGFR inhibitor, and it may exert oncogenic role via promotion of EMT. Taken together, CALM1 may be a tempting target to overcome Afatinib resistance.